Contagem regressiva para implementação do Sistema Nacional de Controle de Medicamentos

30 de maio de 2019

Boehringer starts pilot project with R&B Rastreabilidade Brasil

Boehringer Ingelheim is one of the 20 largest companies in the pharmaceutical industry. Family owned since it was founded in 1885, it has about 50,000 employees who create value through innovation every day for the three business areas: human health, animal health and manufacturing of biopharmaceuticals.

Headquartered in Ingelheim, Germany, the company operates globally and in 2018 achieved net sales of around 17.5 billion euros. Investments in research and development accounted for 18% of net sales, about 3.2 billion euros.

In Brazil, Boehringer Ingelheim has offices in São Paulo and Campinas, and factories in Itapecerica da Serra and Paulínia. For more than 60 years in the country, the company has established partnerships with local and international institutions that promote the educational, social and professional development of the population.

In line with ANVISA legislation, Boehringer Ingelheim started the pilot project on drug traceability with R&B. R&B Pharma and GetPharma products will be responsible for managing pharmaceutical traceability data from the shop floor – at the time of serialization – to communication with the ANVISA database and partners in the supply chain.

It is worth mentioning that by April 2022, the entire Brazilian pharmaceutical chain must comply with the drug traceability law (RDC 157), regulated in 2017 by ANVISA and currently in the pilot phase.

This will be another case implemented by R&B in 2019. To know more Rastreabilidade Brasil products, visit our page.

Fale conosco

Mensagem